Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Gloria Iacoboni; Kai Rejeski; Guillermo Villacampa; Jaap A van Doesum; Annalisa Chiappella; Francesca Bonifazi; Lucia Lopez-Corral; Michiel van Aalderen; Mi Kwon; Nuria Martínez-Cibrian; Stefania Bramanti; Juan Luis Reguera-Ortega; Lina Camacho-Arteaga; Christian Schmidt; Ana Marín-Niebla; Marie José Kersten; Alejandro Martin Garcia-Sancho; Pier Luigi Zinzani; Paolo Corradini; Tom van Meerten; Marion Subklewe; Pere Barba

doi:10.1182/bloodadvances.2021006922

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922.

Authors

Gloria Iacoboni^{1

2}, Kai Rejeski³, Guillermo Villacampa^{4

5

6}, Jaap A van Doesum⁷, Annalisa Chiappella⁸, Francesca Bonifazi⁹, Lucia Lopez-Corral^{10

11}, Michiel van Aalderen¹², Mi Kwon^{13

14}, Nuria Martínez-Cibrian¹⁵, Stefania Bramanti¹⁶, Juan Luis Reguera-Ortega¹⁷, Lina Camacho-Arteaga^{18

19

20}, Christian Schmidt³, Ana Marín-Niebla^{1

2}, Marie José Kersten¹², Alejandro Martin Garcia-Sancho¹⁰, Pier Luigi Zinzani^{9

21}, Paolo Corradini⁸, Tom van Meerten⁷, Marion Subklewe³, Pere Barba^{1

2}

Affiliations

¹ Department of Hematology, Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
² Department of Medicine, Universitat Autònoma de Barcelona, Bellaterra, Spain.
³ Department of Medicine III, University Hospital, LMU Munich, Munich, Germany.
⁴ Oncology Data Science, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
⁵ SOLTI Breast Cancer Research Group, Barcelona, Spain.
⁶ The Institute of Cancer Research, London, United Kingdom.
⁷ Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
⁸ Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
⁹ IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", Bologna, Italy.
¹⁰ Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.
¹¹ Centro de Investigación del Cáncer-IBMCC, Salamanca, Spain.
¹² Department of Hematology, Amsterdam University Medical Centers, Cancer Center Amsterdam, LYMMCARE (Lymphoma and Myeloma Center Amsterdam), Amsterdam, The Netherlands.
¹³ Department of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
¹⁴ Gregorio Marañón Health Research Institute, Madrid, Spain.
¹⁵ Department of Hematology, Hospital Clinic, Barcelona, Spain.
¹⁶ Istituto Clinico Humanitas IRCCS, Rozzano, Italy.
¹⁷ Department of Hematology, University Hospital Virgen del Rocio, Sevilla, Spain.
¹⁸ Clinical Pharmacology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
¹⁹ Clinical Pharmacology, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Barcelona, Spain.
²⁰ Department of Pharmacology, Therapeutics and Toxicology, Autonomous University of Barcelona, Barcelona, Spain; and.
²¹ Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.

No abstract available

MeSH terms

Adult
Antineoplastic Agents* / therapeutic use
Humans
Immunotherapy, Adoptive
Lymphoma, Mantle-Cell* / drug therapy
Lymphoma, Mantle-Cell* / pathology
Neoplasm Recurrence, Local / drug therapy
Pyrimidines / therapeutic use
Receptors, Chimeric Antigen

Substances

Antineoplastic Agents
Pyrimidines
Receptors, Chimeric Antigen
brexucabtagene autoleucel